Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from CSL ( (AU:CSL) ) is now available.
CSL Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 773,583 securities bought back before the previous day and an additional 132,682 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and return value to shareholders, potentially enhancing the company’s stock performance and market perception.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and distribution of innovative biopharmaceutical products. The company is known for its work in producing vaccines, blood plasma derivatives, and other critical medical therapies, serving a global market with a strong emphasis on addressing rare and serious diseases.
Average Trading Volume: 1,066,169
Technical Sentiment Signal: Sell
Current Market Cap: A$99.2B
See more insights into CSL stock on TipRanks’ Stock Analysis page.